Monitoring individual response to hormone replacement therapy with bone markers
- 19 May 2000
- Vol. 26 (6) , 553-560
- https://doi.org/10.1016/s8756-3282(00)00271-4
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- A dose-ranging trial of a matrix transdermal 17β-estradiol for the prevention of bone loss in early postmenopausal womenBone, 1999
- Variability and Response of Urinary Resorption Markers to Hormone Replacement TherapyJournal of Bone and Mineral Research, 1999
- Increased bone turnover in late postmenopausal women is a major determinant of osteoporosisJournal of Bone and Mineral Research, 1996
- Accurate assessment of precision errors: How to measure the reproducibility of bone densitometry techniquesOsteoporosis International, 1995
- Biochemical markers of bone turnover to monitor the bone response to postmenopausal hormone replacement therapyOsteoporosis International, 1995
- Cyclical clodronate is effective in preventing postmenopausal bone loss: A comparative study with transcutaneous hormone replacement therapyJournal of Bone and Mineral Research, 1995
- Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone diseaseJournal of Clinical Endocrinology & Metabolism, 1994
- Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone diseaseJournal of Clinical Endocrinology & Metabolism, 1993
- Measurement of serum osteocalcin with a human-specific two-site immunoradiometric assayJournal of Bone and Mineral Research, 1992
- Decreased Risk of Fractures of the Hip and Lower Forearm with Postmenopausal Use of EstrogenNew England Journal of Medicine, 1980